United Therapeutics Corporation ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für United Therapeutics Corporation zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um United Therapeutics Corporation zu Deinem Portfolio hinzuzufügen.
United Therapeutics Corporation ( UTHR ) Q3 2025 Earnings Call October 29, 2025 9:00 AM EDT Company Participants Harrison Silvers - Manager of Investor Relations Martine Rothblatt - Founder, Chairman & CEO Michael Benkowitz - President & COO Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Patrick Poisson - Executive VP of Technical Operations Conference Ca...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso® and Orenitram®. Total revenues in the third quarter of 2025 grew seven percent year-ov...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a publ...
SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events includi...
United Therapeutics Corporation - Special Call Company Participants Harrison Silvers - Manager of Investor Relations Leigh Peterson - Executive Vice President of Product Development & Xenotransplantation Martine Rothblatt - Founder, Chairman & CEO Conference Call Participants Steven D. Nathan Olivia Brayer - Cantor Fitzgerald & Co., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., ...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) on Sunday, September 28, 2025, at 12:30 p.m. East...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.